CI
UTHR icon

Cambiar Investors’s United Therapeutics UTHR Stock Holding History

Cambiar Investors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-22,485
Closed -$2.51M – 154
2016
Q1 		$2.51M Buy
22,485
+4,426
+25% +$560K 0.04% 132
2015
Q4 		$2.83M Buy
18,059
+1,085
+6% +$158K 0.04% 121
2015
Q3 		$2.23M Buy
+16,974
New +$2.72M 0.03% 149
2013
Q4 		– Sell
-4,820
Closed -$380K – 163
2013
Q3 		$380K Buy
+4,820
New +$352K 0.01% 122

Other funds holding UTHR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cambiar Investors's UTHR Position: Q2 2016 in Review

Cambiar Investors sold out of United Therapeutics (UTHR) in Q2 2016, closing a stake of 22,485 shares — an estimated $2.51M sold.

Cambiar Investors first reported a position in UTHR in Q3 2013 and held it in 4 quarters. The position peaked at $2.83M in Q4 2015. 384 funds tracked by Wall St. Rank hold UTHR as of Q2 2016.

  • Cambiar Investors reported no remaining United Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Cambiar Investors sold 22,485 United Therapeutics shares in Q2 2016, an estimated $2.51M.
  • Cambiar Investors first reported a position in United Therapeutics in Q3 2013 and held it in 4 quarters.
  • Cambiar Investors's United Therapeutics position peaked at $2.83M in Q4 2015.
  • 384 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2016.

Based on Cambiar Investors's 13F filing for Q2 2016, filed 27 Jul 2016.